Early relapse of follicular lymphoma may increase risk of death

the ONA take:

Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients, according to a new study published online ahead of print in the Journal of Clinical Oncology.

Researchers at the University of Rochester in New York and colleagues analyzed data from the National LymphoCare Study in order to evaluate whether patients with follicular lymphoma who experience progression of disease within 2 years of initial R-CHOP therapy have an increased risk of death.

Results showed that the 5-year overall survival was 50% for those who experienced early progression of disease compared with 90% among those who did not.

"Through research we have confirmed that all relapsed patients are not equal, and therefore should not be approached the same at diagnosis nor at the time of relapse in terms of therapies," Carla Casulo, MD, oncologist and assistant professor of Medicine at the University of Rochester said.

Early relapse of follicular lymphoma may increase risk of death
Early relapse of follicular lymphoma could be carefully considered when making decisions about treatment for these patients.
Early relapse should be carefully considered when oncologists and patients make decisions about treatment, concludes a team led by Carla Casulo, oncologist and assistant professor of Medicine at the University of Rochester, NY.
READ FULL ARTICLE From Medical News Today
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs